Abstract
Background: Approximately one million cancer patients live in Ukraine. These persons are at a high risk of manifestation of psychiatric disorders, especially depressive spectrum disorders and anxiety disorders, which may be treated with antidepressants if indications are present. Besides, oncological patients suffer from a number of miscellaneous somatic and psychosomatic conditions, that may also be totally or partly alleviated by using antidepressants. Thus, proper safe and evidence-based usage of these drugs is required. Unfortunately, there’s a lack of Ukrainian scientific literature highlighting this issue. This review is published to fulfill the aforementioned gap.
Objectives: To survey the usage of antidepressants in the cohort of cancer patients, to evaluate a modern state of evidence base concerning this issue, and to study indications, contraindications, and other peculiarities in respect of prescribing these drugs to oncological patients.
Methods: We reviewed and analyzed literature (meta-analyses, RTCs, observational studies, case studies) published in the last 10 years by searching PubMed and Google Scholar. We used the following keywords: “antidepressants”, “oncology”, “cancer”, “cancer symptoms”, “depression” and “drug interaction”. For our purposes, we also used NCCN, ASCO, ESMO, IPOS guidelines in case they were available and concerned our subject.
Results: The review focuses attention on the usage of antidepressants in oncological patients. Best-practice recommendations for choosing a drug are given, information on a drug-to-drug interaction with chemotherapy and other common in oncology drugs, issues with regard to comorbid somatic problems that define prescribing, and off-label indications (pain, hot flushes, pruritus, etc.) are discussed.
Conclusion: Despite the paucity of high-quality researches, a huge amount of evidences support the statement, that antidepressants significantly improve cancer patients’ quality of life by ceasing both depressive/anxious symptoms and typical cancer-related symptoms. To provide best professional help with these drugs, implementation of guidelines recommendations as well as adherence to experience collected from prescribing antidepressants to non-cancer population, which supports the effectiveness of this class of drugs for the treatment of depression, anxiety and pain are essential.
Full-text of the article is available for this locale: Українська.
References
- Fedorenko ZP, Michailovich YY., Goulak LO et al. Cancer in Ukraine, 2016-2017. National Cancer Institute of Ukraine. http://www.ncru.inf.ua/publications/BULL_19/index_e.htm Опубліковано 2018. Процитовано 9 червня 2019.
- Statistics. NIH. https://cancercontrol.cancer.gov/ocs/statistics/statistics.html. Опубліковано 2019. Процитовано 9 червня 2019.
- Kuhnt S, Brähler E, Faller H, et al. Twelve-Month and Lifetime Prevalence of Mental Disorders in Cancer Patients. Psychother Psychosom. 2016;85(5):289-96. https://doi.org/10.1159/000446991 https://www.ncbi.nlm.nih.gov/pubmed/27508418
- Pearson S, Abrahamowicz M, Srasuebkul P, Buckley N. Antidepressant therapy in cancer patients: initiation and factors associated with treatment. Pharmacoepidemiol Drug Saf. 2015;24(6):600-9. https://doi.org/10.1002/pds.3753 https://www.ncbi.nlm.nih.gov/pubmed/25858166
- Ostuzzi G, Matcham F, Dauchy S, Barbui C, Hotopf M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2018;4:CD011006. https://doi.org/10.1002/14651858.CD011006.pub3 https://www.ncbi.nlm.nih.gov/pubmed/29683474
- Callari A, Mauri M, Miniati M, et al. Treatment of depression in patients with breast cancer: a critical review. Tumori. 2013;99(5):623-33. https://doi.org/10.1700/1377.15313 https://www.ncbi.nlm.nih.gov/pubmed/24362868
- Laoutidis Z.G., Mathiak K. Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry. 2013;13:140. https://doi.org/10.1186/1471-244X-13-140 https://www.ncbi.nlm.nih.gov/pubmed/23679841
- Riblet N, Larson R, Watts BV, Holtzheimer P. Reevaluating the role of antidepressants in cancer-related depression: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2014;36(5):466-73. https://doi.org/10.1016/j.genhosppsych.2014.05.010 https://www.ncbi.nlm.nih.gov/pubmed/24950919
- Toftegård Andersen L, Voigt Hansen M, Rosenberg J, Gögenur I. Pharmacological treatment of depression in women with breast cancer: a systematic review. Breast Cancer Res Treat. 2013;141(3):325-30. https://doi.org/10.1007/s10549-013-2708-6 https://www.ncbi.nlm.nih.gov/pubmed/24077731
- Li M, Kennedy EB, Byrne N, et al. Systematic review and meta-analysis of collaborative care interventions for depression in patients with cancer. Psychooncology.2017;26(5):573-87. https://doi.org/10.1002/pon.4286 https://www.ncbi.nlm.nih.gov/pubmed/27643388
- Li M, Kennedy EB, Byrne N, et al. Management of Depression in Patients With Cancer: A Clinical Practice Guideline. J Oncol Pract. 2016;12(8):747-56. https://doi.org/10.1200/JOP.2016.011072 https://www.ncbi.nlm.nih.gov/pubmed/27382000
- Howell D, Keshavarz H, Esplen M et al. Pan-Canadian Practice Guideline: Screening, Assessment and Management of Psychosocial Distress, Depression and Anxiety in Adults with Cancer. Canadian Association of Psychosocial Oncology. https://www.capo.ca/resources/Documents/Guidelines/3APAN-~1.PDF. Опубліковано 2015. Процитовано 9 червня 2018.
- Distress Management. NCCN. https://www.nccn.org/professionals/physician_gls/pdf/distress.pdf. Опубліковано 2019. Процитовано 9 червня 2019.
- Survivorship. NCCN. https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf. Опубліковано 2019. Процитовано 9 червня 2019.
- Grassi L, Nanni MG, Rodin G, Li M, Caruso R. The use of antidepressants in oncology: a review and practical tips for oncologists. Ann Oncol. 2018;29(1):101-11. https://doi.org/10.1093/annonc/mdx526 https://www.ncbi.nlm.nih.gov/pubmed/29272358
- Thekdi SM, Trinidad A, Roth A. Psychopharmacology in cancer. Curr Psychiatry Rep.2015;17(1):529. https://doi.org/10.1007/s11920-014-0529-x https://www.ncbi.nlm.nih.gov/pubmed/25417593
- Sarkar S, Schaefer M. Antidepressant pretreatment for the prevention of interferon alfa-associated depression: a systematic review and meta-analysis. Psychosomatics. 2014;55(3):221-34. https://doi.org/10.1016/j.psym.2013.06.015 https://www.ncbi.nlm.nih.gov/pubmed/24012293
- Lydiatt WM, Bessette D, Schmid KK, Sayles H, Burke WJ. Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer: randomized, double-blind, placebo-controlled clinical trial. JAMA Otolaryngol Head Neck Surg.2013;139(7):678-86. https://doi.org/10.1001/jamaoto.2013.3371 https://www.ncbi.nlm.nih.gov/pubmed/23788218
- Lopez-Martin C, Garrido Siles M, Alcaide-Garcia J, Faus Felipe V. Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience. Int J Clin Pharm. 2014;36(6):1251-9. https://doi.org/10.1007/s11096-014-0029-4 https://www.ncbi.nlm.nih.gov/pubmed/25326824
- Miguel C, Albuquerque E. Drug interaction in psycho-oncology: antidepressants and antineoplastics. Pharmacology. 2011;88(5-6):333-9. https://doi.org/10.1159/000334738 https://www.ncbi.nlm.nih.gov/pubmed/22123153
- Caraci F, Crupi R, Drago F, Spina E. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab. 2011;12(6):570-7. https://doi.org/10.2174/138920011795713706 https://www.ncbi.nlm.nih.gov/pubmed/21395523
- Haque R, Shi J, Schottinger JE, et al. Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors. J Natl Cancer Inst. 2016;108(3): djv337 https://doi.org/10.1093/jnci/djv337 https://www.ncbi.nlm.nih.gov/pubmed/26631176
- Reinert C, Ribas M, Zimmermann P. Drug interactions between antineoplastic and antidepressant agents: analysis of patients seen at an oncology clinic at a general hospital. Trends Psychiatry Psychother. 2015;37(2):87-93. https://doi.org/10.1590/2237-6089-2015-0003 https://www.ncbi.nlm.nih.gov/pubmed/26222300
- Province MA, Goetz MP, Brauch H, et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther.2014;95(2):216-27. https://doi.org/10.1038/clpt.2013.186 https://www.ncbi.nlm.nih.gov/pubmed/24060820
- Donneyong MM, Bykov K, Bosco-Levy P, Dong YH, Levin R, Gagne JJ. Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. BMJ. 2016;354:i5014. https://doi.org/10.1136/bmj.i5014 https://www.ncbi.nlm.nih.gov/pubmed/27694571
- Rogala BG, Charpentier MM, Nguyen MK, Landolf KM, Hamad L, Gaertner KM. Oral Anticancer Therapy: Management of Drug Interactions. J Oncol Pract. 2019;15(2):81-90. https://doi.org/10.1200/JOP.18.00483 https://www.ncbi.nlm.nih.gov/pubmed/30763198
- Gjestad C, Westin AA, Skogvoll E, Spigset O. Effect of Proton Pump Inhibitors on the Serum Concentrations of the Selective Serotonin Reuptake Inhibitors Citalopram, Escitalopram, and Sertraline. Ther Drug Monit. 2015;37(1):90-97. https://doi.org/10.1097/FTD.0000000000000101 https://www.ncbi.nlm.nih.gov/pubmed/24887634
- Benoist GE, Hendriks RJ, Mulders PF, et al. Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. Clin Pharmacokinet. 2016;55(11):1369-80. https://doi.org/10.1007/s40262-016-0403-6 https://www.ncbi.nlm.nih.gov/pubmed/27106175
- Del Re M, Fogli S, Derosa L, et al. The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treat Rev. 2017;55:71-82. https://doi.org/10.1016/j.ctrv.2017.03.001 https://www.ncbi.nlm.nih.gov/pubmed/28340451
- Wang RZ, Vashistha V, Kaur S, Houchens NW. Serotonin syndrome: Preventing, recognizing, and treating it. Cleve Clin J Med. 2016;83(11):810-7. https://doi.org/10.3949/ccjm.83a.15129 https://www.ncbi.nlm.nih.gov/pubmed/27824534
- Kraft SL, Baker NM, Carpenter J, Bostwick JR. Procarbazine and antidepressants: a retrospective review of the risk of serotonin toxicity. Psychooncology. 2014;23(1):108-13. https://doi.org/10.1002/pon.3378 https://www.ncbi.nlm.nih.gov/pubmed/24038727
- FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. FDA. https://www.fda.gov/Drugs/DrugSafety/ucm489676.htm Опубліковано 2016. Процитовано 9 червня 2019.
- Baldo, B. Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch Toxicol. 2018;92(8):2457-73. https://doi.org/10.1007/s00204-018-2244-6 https://www.ncbi.nlm.nih.gov/pubmed/29916050
- Kanner A.M. Most antidepressant drugs are safe for patients with epilepsy at therapeutic doses: A review of the evidence. Epilepsy Behav. 2016;61:282-6. https://doi.org/10.1016/j.yebeh.2016.03.022 https://www.ncbi.nlm.nih.gov/pubmed/27236241
- Hassamal S, Miotto K, Dale W, Danovitch I. Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures. Am J Med. 2018;131(11):1382.e1-1382.e6. https://doi.org/10.1016/j.amjmed.2018.04.025 https://www.ncbi.nlm.nih.gov/pubmed/29752906
- Foong AL, Grindrod KA, Patel T, Kellar J. Demystifying serotonin syndrome (or serotonin toxicity). Can Fam Physician. 2018;64(10):720—27. https://www.ncbi.nlm.nih.gov/pubmed/30315014
- Hoirisch-Clapauch, S., Nardi, A., Gris, J. and Brenner, B. Are the antiplatelet and profibrinolytic properties of selective serotonin-reuptake inhibitors relevant to their brain effects? Thromb Res. 2014;134(1):11-16. https://doi.org/10.1016/j.thromres.2014.02.028 https://www.ncbi.nlm.nih.gov/pubmed/24661990
- Jiang HY, Chen HZ, Hu XJ, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13(1):42-50.e3. https://doi.org/10.1016/j.cgh.2014.06.021 https://www.ncbi.nlm.nih.gov/pubmed/24993365
- Laporte S, Chapelle C, Caillet P et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies. Pharmacol Res. 2017;118:19-32. https://doi.org/10.1016/j.phrs.2016.08.017 https://www.ncbi.nlm.nih.gov/pubmed/27521835
- Gahr M, Zeiss R, Lang D, et al. Risk of bleeding related to selective and non-selective serotonergic antidepressants: a case/non-case approach using data from two pharmacovigilance databases. Pharmacopsychiatry. 2015;48(1):19-24. https://doi.org/10.1055/s-0034-1394398 https://www.ncbi.nlm.nih.gov/pubmed/25376976
- Schäfer C, O'Meara A, Tsakiris DA, Medinger M, Passweg JR, Stern M. Influence of selective serotonin reuptake inhibitors on bleeding risk in patients with severe thrombocytopenia after chemotherapy: a retrospective study. Acta Haematol. 2015;133(3):317-20. https://doi.org/10.1159/000366551 https://www.ncbi.nlm.nih.gov/pubmed/25471100
- Remeron® (mirtazapine) tablets. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020415s023s024.pdf. Опубліковано 2010. Процитовано 9 червня 2019.
- Selami TK, Erdogan E, Azap OK. Mirtazapine-induced thrombocytopenia and neutropenia. Turk J Hematol. 2012;29(3): 297-98 https://doi.org/10.5505/tjh.2012.72325
- Stall N, Godwin J, Juurlink D. Bupropion abuse and overdose. CMAJ. 2014;186(13):1015. https://doi.org/10.1503/cmaj.131534 https://www.ncbi.nlm.nih.gov/pubmed/24778361
- Armstrong, TS., Grant, R, Gilbert, MR, Lee, JW, Norden, AD. Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy. Neuro Oncol. 2016;18(6): 779-89. https://doi.org/10.1093/neuonc/nov269 https://www.ncbi.nlm.nih.gov/pubmed/26527735
- Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother Psychosom. 2016;85(5):270-88. https://doi.org/10.1159/000447034 https://www.ncbi.nlm.nih.gov/pubmed/27508501
- Alkan A, Yaşar A, Karcı E, et al. Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients. Support Care Cancer. 2017;25(1):229-36. https://doi.org/10.1007/s00520-016-3409-6 https://www.ncbi.nlm.nih.gov/pubmed/27619388
- Viramontes TS, Truong H, Linnebur SA. Antidepressant-Induced Hyponatremia in Older Adults. Consult Pharm. 2016;31(3):139-50. https://doi.org/10.4140/TCP.n.2016.139 https://www.ncbi.nlm.nih.gov/pubmed/26975593 ‘
- Grover S., Shouan A., Mehra A., Chakrabarti S., Avasthi, A. Antidepressant-associated hyponatremia among the elderly: A retrospective study. J Geriatr Ment Health. 2018; 5(2):115-20 https://doi.org/10.4103/jgmh.jgmh_28_18
- Liamis G., Megapanou E., Elisaf M., Milionis H.. Hyponatremia-Inducing Drugs. In: Peri, A., Thompson, Chris J., Verbalis, J. G. , ed. Disorders of Fluid and Electrolyte Metabolism Focus on Hyponatremia. Basel: Karger; 2019: 167—177. https://doi.org/10.1159/000493246 ISBN: 978-3-318-06382-0
- Sheng J, Liu S, Wang Y, Cui R, Zhang X. The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain. Neural Plast. 2017;2017:9724371. https://doi.org/10.1155/2017/9724371 https://www.ncbi.nlm.nih.gov/pubmed/28706741
- Fallon M, Giusti R, Aielli F et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29 (Supplement 4):iv166-iv191. https://doi.org/10.1093/annonc/mdy152 https://www.ncbi.nlm.nih.gov/pubmed/30052758
- Adult Cancer Pain. NCCN. https://www.nccn.org/professionals/physician_gls/PDF/pain.pdf. Опубліковано 2019. Процитовано 9 червня 2019.
- Obata H. Analgesic Mechanisms of Antidepressants for Neuropathic Pain. International Journal of Molecular Science.2017;18(11):E2483. https://doi.org/10.3390/ijms18112483 https://www.ncbi.nlm.nih.gov/pubmed/29160850
- Pachman DR, Barton DL, Swetz KM, Loprinzi CL. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol. 2012;30(30):3687-96. https://doi.org/10.1200/JCO.2012.41.7238 https://www.ncbi.nlm.nih.gov/pubmed/23008320
- Tanimukai H, Murai T, Okazaki N et al. An Observational Study of Insomnia and Nightmare Treated With Trazodone in Patients With Advanced Cancer. Am J Hosp Palliat Care. 2013;30(4):359-62. https://doi.org/10.1177/1049909112452334 https://www.ncbi.nlm.nih.gov/pubmed/22777411
- Palliative Care. NCCN. https://www.nccn.org/professionals/physician_gls/pdf/palliative.pdf . Опубліковано 2019. Процитовано 9 червня 2019.
- Riechelmann RP, Burman D, Tannock IF, Rodin G, Zimmermann C. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am J Hosp Palliat Care.2010;27(2):106-10. https://doi.org/10.1177/1049909109345685 https://www.ncbi.nlm.nih.gov/pubmed/19776373
- Jiang SM, Wu JH, Jia L. Intervention of mirtazapine on gemcitabine-induced mild cachexia in nude mice with pancreatic carcinoma xenografts. World J Gastroenterol. 2012;18(22):2867-71. https://doi.org/10.3748/wjg.v18.i22.2867 https://www.ncbi.nlm.nih.gov/pubmed/22719198
- Ashrafi, F., Mousavi, S., Karimi, M. Potential Role of Bupropion Sustained Release for Cancer-Related Fatigue: a Double-Blind, Placebo-Controlled Study. Asian Paс J Cancer Prev. 2018;19(6): 1547—51. https://doi.org/10.22034/APJCP.2018.19.6.1547 https://www.ncbi.nlm.nih.gov/pubmed/29936730
- Cancer-Related Fatigue. NCCN. https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf. Опубліковано 2019. Процитовано 9 червня 2019.
- Woyka J. Consensus statement for non-hormonal-based treatments for menopausal symptoms. Post Reprod Health. 2017;23(2):71-5. https://doi.org/10.1177/2053369117711646 https://www.ncbi.nlm.nih.gov/pubmed/28643614
- Leon-Ferre RA, Majithia N, Loprinzi CL. Management of hot flashes in women with breast cancer receiving ovarian function suppression. Cancer Treat Rev. 2017;52:82-90. https://doi.org/10.1016/j.ctrv.2016.11.012. https://www.ncbi.nlm.nih.gov/pubmed/27960127
- Orleans RJ, Li L, Kim MJ et al. FDA approval of paroxetine for menopausal hot flushes.N Engl J Med. 2014;370(19):1777-9. https://doi.rog.ua/10.1056/NEJMp1402080 https://www.ncbi.nlm.nih.gov/pubmed/24806158
- Faubion SS, Loprinzi CL, Ruddy KJ. Management of Hormone Deprivation Symptoms After Cancer. Mayo Clin Proc. 2016;91(8):1133-46. https://doi.org/10.1016/j.mayocp.2016.04.009 https://www.ncbi.nlm.nih.gov/pubmed/27492917
- Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause.2015;22(11):1155-72; quiz 1173-4 https://doi.org/10.1097/GME.0000000000000546 https://www.ncbi.nlm.nih.gov/pubmed/26382310
- Cobin, R., Goodman, N. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Menopause–2017 Update. Endocr Pract. 2018;23(7):869-80. https://doi.org/10.4158/EP171828.PS https://www.ncbi.nlm.nih.gov/pubmed/28703650
- Primary Cutaneous Lymphomas. NCCN. https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf. Опубліковано 2019. Процитовано 9 червня 2019.
- Weisshaar E, Szepietowski J, Dalgard F et al. European S2k Guideline on Chronic Pruritus. Acta Derm Venereol. 2019;99(5):469-506. https://doi.org/10.2340/00015555-3164 https://www.ncbi.nlm.nih.gov/pubmed/30931482
- Kouwenhoven TA, van de Kerkhof PCM, Kamsteeg M. Use of oral antidepressants in patients with chronic pruritus: A systematic review. J Am Acad Dermatol. 2017;77(6):1068-1073.e7.
- https://doi.org/10.1016/j.jaad.2017.08.025 https://www.ncbi.nlm.nih.gov/pubmed/29033248
- Kaur R., Sinha VR. Antidepressants as antipruritic agents: A review. Eur Neuropsychopharmacol. 2018;28(3):341-52. https://doi.org/10.1016/j.euroneuro.2018.01.007 https://www.ncbi.nlm.nih.gov/pubmed/29456150
- Pongcharoen P, Fleischer AB. Itch Management: Systemic Agents. Curr Probl Dermatol.2016;50:46-53. https://doi.org/10.1159/000446041 https://www.ncbi.nlm.nih.gov/pubmed/27578071